Advanced Technology Ventures
Advanced Technology Ventures (ATV) is a bi-coastal venture capital firm with more than $1.8 billion in capital under management. The firm works with entrepreneurial teams in several technology markets, including IT, healthcare and cleantech, to transform emerging growth companies into market leaders. Founded in 1979, ATV has an established track record of success helping to build strong, sustainable companies.
Clarus Ventures is a life sciences venture capital firm founded by a team of accomplished investment professionals with extensive and complementary industry backgrounds that have enabled them to establish a long history of success in creating value. Its deep relationships with world thought leaders and decision makers allows this team to identify unique investment opportunities and shepherd them to maturity. Clarus augments its core expertise of investing in biopharmaceuticals and medical technology companies with the deep and diverse expertise of the team in research and development, commercialization, business development and operations management at the global level. Clarus has $1.2 billion of assets under management across two lifesciences dedicated funds. Clarus is headquartered in Cambridge, Mass., and has an office in South San Francisco, Calif.
Lightstone Ventures was founded in 2012 by the General Partners and other key members of the life science teams of Advanced Technology Ventures (ATV) and Morgenthaler. The firm was formed to capture the upside of investing in breakthrough life science companies during a time of unique opportunity in the space.
Since 2002, MedImmune Ventures (MV) has been fostering innovation and entrepreneurship by investing in healthcare startup companies. Originally established by the founders of MedImmune, MV is seeking today to deliver superior financial returns by investing in private biopharmaceutical, medical technology and healthcare IT companies across therapeutic areas and geographies. Its investment philosophy is to partner with management teams to advance cutting-edge science and develop novel therapies for patients in need.
SV Life Sciences
SV Life Sciences is a leading international life sciences venture capital firm. SVLS affiliated funds have been investing in life sciences companies since the early 1980s and the firm closed its first dedicated life sciences fund in 1994. The SVLS team manages five venture capital funds and a publicly traded investment trust with approximately $2 billion of capital under management. The firm employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and healthcare services. SVLS has offices in Boston, London and San Francisco.